Use of anticoagulation in cadaver renal transplants

Soper, William D.; Pollak, Raymond; Manaligod, José R.; T, Hau; Mozes, Martin F.; Jonasson, Olga

doi:10.1016/0022-4804(82)90115-9

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, while some suggest beneficial effects of such treatment [2,3], others do not confirm these results [4,5]. Our preliminary results with a new antithrombotic agent, defibrotide, show that while it does not affect the onset of graft rejection, it may prevent or reduce the occur rence of graft vascular damage, therefore im proving graft survival.…”

Section: Resultsmentioning

confidence: 71%

“…Their presence is generally associated with poor prognosis for the graft [1]. Many attempts have been made to prevent vascular damage by giving warfarin, heparin, acetyl salicylic acid and dipyridamole [2,5], but the results are often conflicting. Moreover, undesirable side effects may occur [2,4,5], which argues against the clinical use of these drugs in cur rent practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Defibrotide in Renal Transplantation in Man

Bonomini¹,

Vangelista²,

Stefoni³

et al. 1986

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

In transplanted patients graft rejection is the most frequent complication in the first year after surgery. Vascular lesions (necrosis, intimal proliferation, thrombosis) are signs of poor prognosis and lead to irreversible loss of renal function and graft removal in most cases. The problem of vascular rejection is still not solved and the results of therapy unsatisfactory, both because of inadequacy of diagnosis and/or inadequacy of available therapy. The role of prevention, very likely the best approach, is still sub judice. In an attempt to explore the validity of prevention, 22 transplanted patients (group A) were given a new antithrombotic agent (defibrotide) immediately after surgery, and the results were compared with those of a well-matched group of 30 patients on dipyridamole (group B). Follow-up lasted 6–19 months (mean 9.9) for group A; 5–21 months (mean 12) for group B. In group A, 8 patients (36%) had rejection episodes. Antirejection therapy was followed by recovery of renal function in all cases. In group B, 9 patients (29%) had rejection crises and graft removal was necessary in 7 instances due to severe vascular lesions. At the end of follow-up, all patients treated with defibrotide had normally functioning grafts: among the 30 patients on dipyridamole, 22 (73%) had satisfactory graft function.

show abstract

Section: Resultsmentioning

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Use of Defibrotide in Renal Transplantation in Man

Bonomini¹,

Vangelista²,

Stefoni³

et al. 1986

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…Furthermore subse quent studies revealed that since heparin prevents release of prostacyclin from the vascular endothelium, it can promote platelet aggregation [32], Bleeding problems with anticoagulated patients led to its withdrawal from many units [33], although it is pertinent that such units have often not devoted much energy to monitoring of control. Actually warfarin anticoagulation can improve the 3-month cadaver graft survival [7,34,35]. Using histological assessment, Matthew et al [36] showed in creased graft survival at 3 and 6 months and 1 and 2 years with warfarinisation.…”

mentioning

confidence: 99%